Last Update: Nov 19, 2026

 A Phase IIIb, Multi-center, Two-arm, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Zigakibart and Atrasentan Versus Zigakibart and Placebo in Patients With Primary IgA Nephropathy

ClinicalTrials.gov Identifier: [NCT07850752](https://clinicaltrials.gov/ct2/show/NCT07850752)

Novartis Reference Number:CFUB523A12303

 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify")

 All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

##  Study Description

This is a Phase IIIb, multicenter, two-arm, randomized, double-blind, parallel group study to evaluate the efficacy and safety of zigakibart + atrasentan compared to zigakibart + placebo in patients with primary IgAN at risk of disease progression. The study includes a 52-week double-blind treatment period and a 52-week open-label extension (OLE):

\* Double-blind treatment period: Participants will receive zigakibart and either atrasentan or matching placebo. The purpose is to evaluate if zigakibart + atrasentan demonstrates increased efficacy in reducing proteinuria and delaying progression of disease compared to zigakibart + placebo. It also aims to evaluate the safety and tolerability of zigakibart + atrasentan.
 \* OLE: Participants will receive zigakibart and atrasentan. The purpose is to provide study participants with the opportunity to continue to receive zigakibart and atrasentan, while enabling continued collection of long-term efficacy, safety, and tolerability data.

 Condition IgA Nephropathy (IgAN)

 Phase Phase3

 Overall Status Recruiting

 Number of Participants340

 Start Date Nov 11, 2026

 Completion Date Dec 25, 2030

 Gender All

 Age(s) 18 Years - (Adult, Older Adult)

##  Interventions

Drug

### atrasentan

Tablet

Drug

### Placebo

Tablet

Biological

### zigakibart

Solution for injection via PFS-NSD

##  Eligibility Criteria

Inclusion Criteria:

\* Aged ≥ 18 years at the time of signing the informed consent, prior to initiation of any study specific activities/procedures
 \* Biopsy-proven IgAN diagnosed within the past 10 years prior to Screening, that, in the opinion of the Investigator, is not due to secondary causes. If a biopsy report within 10 years is not available, re-biopsy may be performed locally during Screening.
 \* eGFR ≥ 30 mL/min/1.73m2 by a central laboratory at Screening, calculated using serum creatinine based on the 2021 CKD-EPI equation (Inker et al 2021)
 \* UPCR ≥ 0.7 g/g (700 mg/g), as measured from a 24 hour urine collection by a central laboratory at Screening
 \* Stable on a maximally tolerated dose of ACEi and/or ARB for at least 12 weeks prior to Screening unless intolerant to ACEi and ARB. May also be on a stable and well tolerated dose of SGLT2i, MRA, and/or GLP-1A if stable for at least 12 weeks prior to Screening. Participants are expected to stay on a stable dose of ACEi, ARB, SGLT2i, MRA and/or GLP-1A for the duration of the study.

Exclusion Criteria:

\* Chronic Kidney Disease (CKD), either clinically suspected or based on biopsy, resulting from any condition or another glomerulopathy/podocytopathy other than IgAN
 \* Secondary forms of IgAN as determined by the Investigator, in the setting of systemic disorders, infections, autoimmune disorders or neoplasia
 \* Diagnosis of active IgA vasculitis
 \* Clinical suspicion of IgAN with rapidly progressive glomerulonephritis (RPGN) based on Kidney Disease: Improving Global Outcomes (KDIGO) guidelines (2025)
 \* Current clinical diagnosis of nephrotic syndrome
 \* Known history of heart failure or conditions relating to fluid overload such as pulmonary edema, uncontrolled peripheral edema, pleural effusion, or ascites
 \* Current severe infection requiring antimicrobials, or history of recurrent, severe infections as determined by the Investigator

Other protocol-defined inclusion/exclusion criteria may apply

 Australia

####  Novartis Investigative Site

Recruiting

 Nedlands,Western Australia,6009,Australia

 Israel

####  Novartis Investigative Site

Recruiting

 Petah Tikva,4941492,Israel

####  Novartis Investigative Site

Recruiting

 Beersheba,8457108,Israel

 United States

####  Florida Kidney Physicians LLC

Recruiting

 Temple Terrace,Florida,33637,United States

######  Wayne Robert Kotzker

######  Bianca Philippe

Email: <bphilippe@panoramichealth.com>

####  Northern Assoc of Northern VA

Recruiting

 Fairfax,Virginia,22033,United States

######  Musirah Khan

Phone: [+1 703 953 0155](<tel:+1 703 953 0155>)

Email: <Musirah.khan@nanvonline.com>

######  Ahmadshah Mirkhel

####  DaVita Clinical Research

Recruiting

 Las Vegas,Nevada,89146,United States

######  Mark Vishnepolsky

######  Farzana Siddiqui

Email: <farzana.siddiqui@davita.com>

####  Southeast Kidney Associates

Recruiting

 East Point,Georgia,30344,United States

######  Taheerah Watson

Phone: [+1 404 761 0819](<tel:+1 404 761 0819>)

Email: <twatson@panoramichealth.com>

######  Charmaine Emelife

####  Nephrology Consultants LLC

Recruiting

 Huntsville,Alabama,35805,United States

######  Michael Quadrini

######  Natalie Freking

Phone: [+1 256 533 4626](<tel:+1 256 533 4626>)

Email: <nfreking@apogeecr.com>

####  Florida Kidney Physicians

Recruiting

 Riverview,Florida,33578,United States

######  Myra Rodriguez

Email: <mrodriguez@panoramichealth.com>

######  Amit Johnsingh

####  Nephrology Associates PA

Recruiting

 Newark,Delaware,19713,United States

######  Theodore Saad

######  Nicole Davis

Email: <ndavis@delawarekidney.com>

####  West Coast Kidney Institute

Recruiting

 Fremont,California,94538,United States

######  Varun Chawla

######  Gina Samuel

Phone: [+1 510 745 8187](<tel:+1 510 745 8187>)

Email: <gsamuel@panoramichealth.com>

##  Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

#### Novartis Pharmaceuticals

Phone: [ +41613241111](tel:+41613241111)

Email: [](mailto:)

#### Novartis Pharmaceuticals

Phone: [ 1-888-669-6682](tel:1-888-669-6682)

Email: <novartis.email@novartis.com>